[1]
|
Meyers, J., Sabatos, C., Chakravarti, S., et al. (2005) The TIM Gene Family Regulates Autoimmune and Allergic Dis-eases. Trends in Molecular Medicine, 11, 362-369. https://doi.org/10.1016/j.molmed.2005.06.008
|
[2]
|
Saleh, R., Toor, S. and Elkord, E. (2020) Targeting TIM-3 in Solid Tumors: Innovations in the Preclinical and Translational Realm and Therapeutic Potential. Expert Opinion on Therapeutic Targets, 24, 1251-1262.
https://doi.org/10.1080/14728222.2020.1841750
|
[3]
|
Van de Weyer, P., Muehlfeit, M., Klose, C., et al. (2006) A Highly Conserved Tyrosine of Tim-3 Is Phosphorylated upon Stimulation by Its Ligand Galectin-9. Biochemical and Bi-ophysical Research Communications, 351, 571-576.
https://doi.org/10.1016/j.bbrc.2006.10.079
|
[4]
|
Clayton, K., Haaland, M., Douglas-Vail, M., et al. (2014) T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases. Journal of Immunology (Baltimore, MD: 1950), 192, 782-791. https://doi.org/10.4049/jimmunol.1302663
|
[5]
|
Yu, L., Liu, X., Wang, X., et al. (2021) TIGIT TIM-3 NK Cells Are Correlated with NK Cell Exhaustion and Disease Progression in Patients with Hepatitis B Virus-Related Hepatocel-lular Carcinoma. Oncoimmunology, 10, Article ID: 1942673. https://doi.org/10.1080/2162402X.2021.1942673
|
[6]
|
Kandel, S., Adhikary, P., Li, G., et al. (2021) The TIM3/Gal9 Signaling Pathway: An Emerging Target for Cancer Immunotherapy. Cancer Letters, 510, 67-78. https://doi.org/10.1016/j.canlet.2021.04.011
|
[7]
|
Tang, D. and Lotze, M. (2012) Tumor Immunity Times Out: TIM-3 and HMGB1. Nature Immunology, 13, 808-810.
https://doi.org/10.1038/ni.2396
|
[8]
|
Sordi, R., Bet, Â., Della Justina, A., et al. (2020) The Apoptosis Clearance Signal Phosphatidylserine Inhibits Leukocyte Migration and Promotes Inflammation Resolution in Vivo. European Jour-nal of Pharmacology, 877, Article ID: 173095. https://doi.org/10.1016/j.ejphar.2020.173095
|
[9]
|
Freeman, G., Casasnovas, J., Umetsu, D., et al. (2010) TIM Genes: A Family of Cell Surface Phosphatidylserine Receptors That Reg-ulate Innate and Adaptive Immunity. Immunological Reviews, 235, 172-189.
https://doi.org/10.1111/j.0105-2896.2010.00903.x
|
[10]
|
Zang, K., Hui, L., Wang, M., et al. (2021) TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinfor-matics Validation. Frontiers in Oncology, 11, Article 579351. https://doi.org/10.3389/fonc.2021.579351
|
[11]
|
Gao, X., Zhu, Y., Li, G., et al. (2012) TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression. PLOS ONE, 7, e30676. https://doi.org/10.1371/journal.pone.0030676
|
[12]
|
Sun, H., Gao, W., Pan, W., et al. (2017) Tim3+ Foxp3+ Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid Arthritis. Inflammation, 40, 1342-1350. https://doi.org/10.1007/s10753-017-0577-6
|
[13]
|
Huang, S., Liu, D., Sun, J., et al. (2022) Tim-3 Regulates Sepsis-Induced Immunosuppression by Inhibiting the NF-κB Signaling Pathway in CD4 T Cells. Molecular Therapy, 30, 1227-1238. https://doi.org/10.1016/j.ymthe.2021.12.013
|
[14]
|
Han, G., Chen, G., Shen, B., et al. (2013) Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells. Frontiers in Immunology, 4, Article 449. https://doi.org/10.3389/fimmu.2013.00449
|
[15]
|
Li, Y.-H., Zhou, W.-H., Tao, Y., et al. (2016) The Galec-tin-9/Tim-3 Pathway Is Involved in the Regulation of NK Cell Function at the Maternal-Fetal Interface in Early Pregnancy. Cellular & Molecular Immunology, 13, 73-81.
https://doi.org/10.1038/cmi.2014.126
|
[16]
|
Chew, V., Lee, Y., Pan, L., et al. (2019) Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut, 68, 335-346. https://doi.org/10.1136/gutjnl-2017-315485
|
[17]
|
Galluzzi, L., Buqu, A., Kepp, O., et al. (2017) Immunogenic Cell Death in Cancer and Infectious Disease. Nature Reviews Immunology, 17, 97-111. https://doi.org/10.1038/nri.2016.107
|
[18]
|
Chen, Q., Sun, L. and Chen, Z. (2016) Regulation and Function of the cGAS-STING Pathway of Cytosolic DNA Sensing. Nature Immunology, 17, 1142-1149. https://doi.org/10.1038/ni.3558
|
[19]
|
Sun, L., Wu, J., Du, F., et al. (2013) Cyclic GMP-AMP Synthase Is a Cyto-solic DNA Sensor That Activates the Type I Interferon pathway. Science (New York, NY), 339, 786-791. https://doi.org/10.1126/science.1232458
|
[20]
|
Rodriguez-Ruiz, M., Rodriguez, I., Leaman, O., et al. (2019) Immune Mechanisms Mediating Abscopal Effects in Radioimmunotherapy. Pharmacology & Therapeutics, 196, 195-203. https://doi.org/10.1016/j.pharmthera.2018.12.002
|
[21]
|
Sato, H., Niimi, A., Yasuhara, T., et al. (2017) DNA Dou-ble-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells. Nature Communications, 8, Article No. 1751. https://doi.org/10.1038/s41467-017-01883-9
|
[22]
|
Azad, A., Lim, S.Y., D’costa, Z., et al. (2017) PD-L1 Blockade Enhances Response of Pancreatic Ductal Adenocarcinoma to Radiotherapy. EMBO Molecular Medicine, 9, 167-180. https://doi.org/10.15252/emmm.201606674
|
[23]
|
Tu, X., Qin, B., Zhang, Y., et al. (2019) PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radia-tion or Chemotherapy. Molecular Cell, 74, 1215-1226.e4.
https://doi.org/10.1016/j.molcel.2019.04.005
|
[24]
|
Formenti, S., Rudqvist, N., Golden, E., et al. (2018) Radiothera-py Induces Responses of Lung Cancer to CTLA-4 Blockade. Nature Medicine, 24, 1845-1851. https://doi.org/10.1038/s41591-018-0232-2
|
[25]
|
Theelen, W., Peulen, H., Lalezari, F., et al. (2019) Effect of Pem-brolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Ad-vanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1276-1282.
https://doi.org/10.1001/jamaoncol.2019.1478
|
[26]
|
Shaverdian, N., Lisberg, A., Bornazyan, K., et al. (2017) Previ-ous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. https://doi.org/10.1016/S1470-2045(17)30380-7
|
[27]
|
Yamaguchi, O., Kaira, K., Hashimoto, K., et al. (2019) Radi-otherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non-Small Cell Lung Cancer Patients after Treatment with the Immune Checkpoint Inhibitor, Nivolumab. Thoracic Cancer, 10, 992-1000. https://doi.org/10.1111/1759-7714.13044
|
[28]
|
赵春燕, 唐嘉迎. 外周血Tim-3表达水平与食管癌放化疗敏感性的相关性研究[J]. 河北医学, 2021, 27(6): 886-892.
|
[29]
|
Sonanini, D., Griessinger, C., Schörg, B., et al. (2021) Low-Dose Total Body Irradiation Facilitates Antitumoral Th1 Immune Responses. Theranostics, 11, 7700-7714. https://doi.org/10.7150/thno.61459
|
[30]
|
Verbrugge, I., Hagekyriakou, J., Sharp, L., et al. (2012) Radiotherapy In-creases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research, 72, 3163-3174.
https://doi.org/10.1158/0008-5472.CAN-12-0210
|
[31]
|
Ruan, Y., Hu, W., Li, W., et al. (2019) Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy. BioMed Research International, 2019, Article ID: 3939720. https://doi.org/10.1155/2019/3939720
|
[32]
|
Peng, Q., Li, J., Xin, P., et al. (2021) Assessment of the Expression and Response of PD-1, LAG-3, and TIM-3 after Neoadjuvant Radiotherapy in Rectal Cancer. Neoplasma, 68, 742-750.
https://doi.org/10.4149/neo_2021_201210N1341
|
[33]
|
Filatenkov, A., Baker, J., Mueller, A., et al. (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin-ical Cancer Research, 21, 3727-3739.
https://doi.org/10.1158/1078-0432.CCR-14-2824
|
[34]
|
Dong, D.-N., Fan, P.-W., Feng, Y.-N., Liu, G.-H., et al. (2021) Association between Circulating CD39+CD8+ T Cells Pre-Chemoradiotherapy and Prognosis in Patients with Nasopharyngeal Carcinoma. Chinese Medical Journal, 134, 2066-2072. https://doi.org/10.1097/CM9.0000000000001745
|
[35]
|
Liu, M., Li, Z., Yao, W., et al. (2020) IDO Inhibitor Syner-gized with Radiotherapy to Delay Tumor Growth by Reversing T Cell Exhaustion. Molecular Medicine Reports, 21, 445-453. https://doi.org/10.3892/mmr.2019.10816
|
[36]
|
Petersen, S., Kua, L., Nakajima, S., Yong, W., et al. (2021) Chemoradiation Induces Upregulation of Immunogenic Cell Death-Related Molecules Together with Increased Expres-sion of PD-L1 and Galectin-9 in Gastric Cancer. Scientific Reports, 11, Article No. 12264. https://doi.org/10.1038/s41598-021-91603-7
|
[37]
|
Shayan, G., Srivastava, R., Li, J., et al. (2017) Adaptive Re-sistance to Anti-PD1 Therapy by Tim-3 Upregulation Is Mediated by the PI3K-Akt Pathway in Head and Neck Cancer. Oncoimmunology, 6, e1261779.
https://doi.org/10.1080/2162402X.2016.1261779
|
[38]
|
Ngiow, S., Von Scheidt, B., Akiba, H., et al. (2011) An-ti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Research, 71, 3540-3551.
https://doi.org/10.1158/0008-5472.CAN-11-0096
|
[39]
|
Oweida, A., Hararah, M., Phan, A., et al. (2018) Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research, 24, 5368-5380.
https://doi.org/10.1158/1078-0432.CCR-18-1038
|
[40]
|
Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. https://doi.org/10.1016/j.immuni.2016.05.001
|